Aldose reductase in diabetic complications of the eye

Jin H. Kinoshita, Suguru Fukushi, Peter F Kador, Lorenzo O. Merola

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

Aldose reductase (AR) appears to initiate the cataractous process in galactosemic and diabetic animals. Sugars in excess are converted to polyols by lens AR. In sugar cataracts, polyols accumulate to levels substantial enough to cause a hypertonicity leading to lens fiber swelling. All other changes appear secondary to polyol accumulation and lens swelling. The development of sugar cataracts can be duplicated in organ culture. In culture, the various changes that occur were minimized or did not occur when inhibitors of AR were included in the medium. Moreover, AR inhibitors were shown to effectively delay the onset of sugar cataract development in animals. A defect in the corneal epithelium of diabetics became apparent in vitrectomy. One manifestation of this problem was the delay in the reepithelialization of denuded corneas. In examining this problem experimentally, the epithelium was removed from the corneas of diabetic and normal rats. The regeneration of epithelium in corneas of diabetic rats required a longer period than in the normal. The possibility that AR, active in the epithelium, was involved in this phenomenon was investigated. The corneal epithelium was removed from both eyes of a diabetic rat. One eye was treated topically with the AR inhibitor CP-45,634 while the other served as control. The eye treated with CP-45,635 regenerated epithelium much more quickly than the untreated eye. Other AR inhibitors had similar beneficial effects.

Original languageEnglish (US)
Pages (from-to)462-469
Number of pages8
JournalMetabolism
Volume28
Issue number4 SUPPL. 1
DOIs
StatePublished - Jan 1 1979

Fingerprint

Aldehyde Reductase
Diabetes Complications
Epithelium
Cornea
Cataract
Lenses
Corneal Epithelium
Organ Culture Techniques
Vitrectomy
Regeneration

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Kinoshita, J. H., Fukushi, S., Kador, P. F., & Merola, L. O. (1979). Aldose reductase in diabetic complications of the eye. Metabolism, 28(4 SUPPL. 1), 462-469. https://doi.org/10.1016/0026-0495(79)90057-X

Aldose reductase in diabetic complications of the eye. / Kinoshita, Jin H.; Fukushi, Suguru; Kador, Peter F; Merola, Lorenzo O.

In: Metabolism, Vol. 28, No. 4 SUPPL. 1, 01.01.1979, p. 462-469.

Research output: Contribution to journalArticle

Kinoshita, JH, Fukushi, S, Kador, PF & Merola, LO 1979, 'Aldose reductase in diabetic complications of the eye', Metabolism, vol. 28, no. 4 SUPPL. 1, pp. 462-469. https://doi.org/10.1016/0026-0495(79)90057-X
Kinoshita, Jin H. ; Fukushi, Suguru ; Kador, Peter F ; Merola, Lorenzo O. / Aldose reductase in diabetic complications of the eye. In: Metabolism. 1979 ; Vol. 28, No. 4 SUPPL. 1. pp. 462-469.
@article{ed2e2617191d411d82b1bc1bd767c842,
title = "Aldose reductase in diabetic complications of the eye",
abstract = "Aldose reductase (AR) appears to initiate the cataractous process in galactosemic and diabetic animals. Sugars in excess are converted to polyols by lens AR. In sugar cataracts, polyols accumulate to levels substantial enough to cause a hypertonicity leading to lens fiber swelling. All other changes appear secondary to polyol accumulation and lens swelling. The development of sugar cataracts can be duplicated in organ culture. In culture, the various changes that occur were minimized or did not occur when inhibitors of AR were included in the medium. Moreover, AR inhibitors were shown to effectively delay the onset of sugar cataract development in animals. A defect in the corneal epithelium of diabetics became apparent in vitrectomy. One manifestation of this problem was the delay in the reepithelialization of denuded corneas. In examining this problem experimentally, the epithelium was removed from the corneas of diabetic and normal rats. The regeneration of epithelium in corneas of diabetic rats required a longer period than in the normal. The possibility that AR, active in the epithelium, was involved in this phenomenon was investigated. The corneal epithelium was removed from both eyes of a diabetic rat. One eye was treated topically with the AR inhibitor CP-45,634 while the other served as control. The eye treated with CP-45,635 regenerated epithelium much more quickly than the untreated eye. Other AR inhibitors had similar beneficial effects.",
author = "Kinoshita, {Jin H.} and Suguru Fukushi and Kador, {Peter F} and Merola, {Lorenzo O.}",
year = "1979",
month = "1",
day = "1",
doi = "10.1016/0026-0495(79)90057-X",
language = "English (US)",
volume = "28",
pages = "462--469",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Aldose reductase in diabetic complications of the eye

AU - Kinoshita, Jin H.

AU - Fukushi, Suguru

AU - Kador, Peter F

AU - Merola, Lorenzo O.

PY - 1979/1/1

Y1 - 1979/1/1

N2 - Aldose reductase (AR) appears to initiate the cataractous process in galactosemic and diabetic animals. Sugars in excess are converted to polyols by lens AR. In sugar cataracts, polyols accumulate to levels substantial enough to cause a hypertonicity leading to lens fiber swelling. All other changes appear secondary to polyol accumulation and lens swelling. The development of sugar cataracts can be duplicated in organ culture. In culture, the various changes that occur were minimized or did not occur when inhibitors of AR were included in the medium. Moreover, AR inhibitors were shown to effectively delay the onset of sugar cataract development in animals. A defect in the corneal epithelium of diabetics became apparent in vitrectomy. One manifestation of this problem was the delay in the reepithelialization of denuded corneas. In examining this problem experimentally, the epithelium was removed from the corneas of diabetic and normal rats. The regeneration of epithelium in corneas of diabetic rats required a longer period than in the normal. The possibility that AR, active in the epithelium, was involved in this phenomenon was investigated. The corneal epithelium was removed from both eyes of a diabetic rat. One eye was treated topically with the AR inhibitor CP-45,634 while the other served as control. The eye treated with CP-45,635 regenerated epithelium much more quickly than the untreated eye. Other AR inhibitors had similar beneficial effects.

AB - Aldose reductase (AR) appears to initiate the cataractous process in galactosemic and diabetic animals. Sugars in excess are converted to polyols by lens AR. In sugar cataracts, polyols accumulate to levels substantial enough to cause a hypertonicity leading to lens fiber swelling. All other changes appear secondary to polyol accumulation and lens swelling. The development of sugar cataracts can be duplicated in organ culture. In culture, the various changes that occur were minimized or did not occur when inhibitors of AR were included in the medium. Moreover, AR inhibitors were shown to effectively delay the onset of sugar cataract development in animals. A defect in the corneal epithelium of diabetics became apparent in vitrectomy. One manifestation of this problem was the delay in the reepithelialization of denuded corneas. In examining this problem experimentally, the epithelium was removed from the corneas of diabetic and normal rats. The regeneration of epithelium in corneas of diabetic rats required a longer period than in the normal. The possibility that AR, active in the epithelium, was involved in this phenomenon was investigated. The corneal epithelium was removed from both eyes of a diabetic rat. One eye was treated topically with the AR inhibitor CP-45,634 while the other served as control. The eye treated with CP-45,635 regenerated epithelium much more quickly than the untreated eye. Other AR inhibitors had similar beneficial effects.

UR - http://www.scopus.com/inward/record.url?scp=0018748152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018748152&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(79)90057-X

DO - 10.1016/0026-0495(79)90057-X

M3 - Article

VL - 28

SP - 462

EP - 469

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 4 SUPPL. 1

ER -